These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 24872107)

  • 1. Carboplatin plus paclitaxel scheduling for advanced ovarian cancer - authors' reply.
    Pignata S; Di Maio M; Gallo C; Perrone F
    Lancet Oncol; 2014 Jun; 15(7):e250-1. PubMed ID: 24872107
    [No Abstract]   [Full Text] [Related]  

  • 2. Carboplatin plus paclitaxel scheduling for advanced ovarian cancer.
    Shimokata T; Ando Y
    Lancet Oncol; 2014 Jun; 15(7):e249-50. PubMed ID: 24872105
    [No Abstract]   [Full Text] [Related]  

  • 3. Carboplatin plus paclitaxel scheduling for advanced ovarian cancer.
    Baratti D; Kusamura S; Deraco M
    Lancet Oncol; 2014 Jun; 15(7):e249. PubMed ID: 24872106
    [No Abstract]   [Full Text] [Related]  

  • 4. Chemotherapy for ovarian cancer: beyond paclitaxel plus carboplatin.
    Ozols RF
    Cancer J Sci Am; 1999; 5(6):336-8. PubMed ID: 10606473
    [No Abstract]   [Full Text] [Related]  

  • 5. Carboplatin plus paclitaxel once a week versus every 3 weeks in patients with advanced ovarian cancer (MITO-7): a randomised, multicentre, open-label, phase 3 trial.
    Pignata S; Scambia G; Katsaros D; Gallo C; Pujade-Lauraine E; De Placido S; Bologna A; Weber B; Raspagliesi F; Panici PB; Cormio G; Sorio R; Cavazzini MG; Ferrandina G; Breda E; Murgia V; Sacco C; Cinieri S; Salutari V; Ricci C; Pisano C; Greggi S; Lauria R; Lorusso D; Marchetti C; Selvaggi L; Signoriello S; Piccirillo MC; Di Maio M; Perrone F; ; ; ; ;
    Lancet Oncol; 2014 Apr; 15(4):396-405. PubMed ID: 24582486
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Carboplatin and paclitaxel in ovarian cancer.
    Ozols RF
    Semin Oncol; 1995 Jun; 22(3 Suppl 6):78-83. PubMed ID: 7541158
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Topotecan plus carboplatin and paclitaxel in first-line treatment of advanced ovarian cancer: a meta-analysis of randomized controlled trials.
    Zhang H; Jia L; Xu Y; Zhou XC; Kong B; Li D
    J Chemother; 2012 Apr; 24(2):67-73. PubMed ID: 22546760
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Randomized phase 3 trial of interferon gamma-1b plus standard carboplatin/paclitaxel versus carboplatin/paclitaxel alone for first-line treatment of advanced ovarian and primary peritoneal carcinomas: results from a prospectively designed analysis of progression-free survival.
    Alberts DS; Marth C; Alvarez RD; Johnson G; Bidzinski M; Kardatzke DR; Bradford WZ; Loutit J; Kirn DH; Clouser MC; Markman M;
    Gynecol Oncol; 2008 May; 109(2):174-81. PubMed ID: 18314182
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Carboplatin plus paclitaxel versus carboplatin plus pegylated liposomal doxorubicin as first-line treatment for patients with ovarian cancer: the MITO-2 randomized phase III trial.
    Pignata S; Scambia G; Ferrandina G; Savarese A; Sorio R; Breda E; Gebbia V; Musso P; Frigerio L; Del Medico P; Lombardi AV; Febbraro A; Scollo P; Ferro A; Tamberi S; Brandes A; Ravaioli A; Valerio MR; Aitini E; Natale D; Scaltriti L; Greggi S; Pisano C; Lorusso D; Salutari V; Legge F; Di Maio M; Morabito A; Gallo C; Perrone F
    J Clin Oncol; 2011 Sep; 29(27):3628-35. PubMed ID: 21844495
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Paclitaxel plus carboplatin versus standard chemotherapy with either single-agent carboplatin or cyclophosphamide, doxorubicin, and cisplatin in women with ovarian cancer: the ICON3 randomised trial.
    International Collaborative Ovarian Neoplasm Group
    Lancet; 2002 Aug; 360(9332):505-15. PubMed ID: 12241653
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Residual neurotoxicity in ovarian cancer patients in clinical remission after first-line chemotherapy with carboplatin and paclitaxel: the Multicenter Italian Trial in Ovarian cancer (MITO-4) retrospective study.
    Pignata S; De Placido S; Biamonte R; Scambia G; Di Vagno G; Colucci G; Febbraro A; Marinaccio M; Lombardi AV; Manzione L; Cartenì G; Nardi M; Danese S; Valerio MR; de Matteis A; Massidda B; Gasparini G; Di Maio M; Pisano C; Perrone F
    BMC Cancer; 2006 Jan; 6():5. PubMed ID: 16398939
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Paclitaxel (Taxol)/carboplatin combination chemotherapy in the treatment of advanced ovarian cancer.
    Ozols RF
    Semin Oncol; 2000 Jun; 27(3 Suppl 7):3-7. PubMed ID: 10952119
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Adverse effect of paclitaxel plus carboplatin combination therapy related to administration schedule in patients with ovarian cancer].
    Fuse K; Tanaka T; Kagaya H; Suzuki T; Kimura A
    Gan To Kagaku Ryoho; 2001 Sep; 28(9):1295-7. PubMed ID: 11579644
    [No Abstract]   [Full Text] [Related]  

  • 14. Carboplatin plus paclitaxel as first-line chemotherapy in previously untreated advanced ovarian cancer. German AGO Study Group Ovarian Cancer. Arbeitsgemeinschaft Gynäkologische Onkologie.
    du Bois A; Lück HJ; Meier W; Möbus V; Costa S; Richter B; Bauknecht T; Warm M; Schroeder W; Olbricht S; Nitz U; Jackisch C
    Semin Oncol; 1997 Aug; 24(4 Suppl 11):S11-28-S11-33. PubMed ID: 9314296
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparisons of the survival time of patients with ovarian cancer adopting post-operative chemotherapy by use of paclitaxel combined with carboplatin or nedaplatin.
    Gao H; Yuan L; Han Y
    World J Surg Oncol; 2016 Jun; 14(1):168. PubMed ID: 27341795
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Paclitaxel/carboplatin versus topotecan/paclitaxel/carboplatin in patients with FIGO suboptimally resected stage III-IV epithelial ovarian cancer a multicenter, randomized study.
    Bolis G; Scarfone G; Raspagliesi F; Mangili G; Danese S; Scollo P; Lo Russo D; Villa A; Aimone PD; Scambia G
    Eur J Cancer; 2010 Nov; 46(16):2905-12. PubMed ID: 20673626
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chemotherapy of advanced ovarian cancer.
    McGuire WP; Ozols RF
    Semin Oncol; 1998 Jun; 25(3):340-8. PubMed ID: 9633846
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Current status of chemotherapy for ovarian cancer.
    Ozols RF
    Semin Oncol; 1995 Oct; 22(5 Suppl 12):61-6. PubMed ID: 7481863
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Carboplatin and Taxol (paclitaxel) in advanced ovarian carcinoma.
    Ozols RF
    Ann Oncol; 1994; 5 Suppl 6():S39-43. PubMed ID: 7865433
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Paclitaxel plus carboplatin in the treatment of ovarian cancer.
    Ozols RF
    Semin Oncol; 1999 Feb; 26(1 Suppl 2):84-9. PubMed ID: 10190787
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.